2008
Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali AC, Bia MJ. Management of Cardiovascular Disease in Renal Transplant Recipients. Clinical Journal Of The American Society Of Nephrology 2008, 3: 491-504. PMID: 18287250, PMCID: PMC6631091, DOI: 10.2215/cjn.05081107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCardiovascular DiseasesDecision TreesDiabetes ComplicationsHumansHyperlipidemiasHypertensionKidney TransplantationPostoperative ComplicationsRisk FactorsConceptsRenal transplant recipientsTransplant recipientsRisk factorsCardiovascular diseaseKidney Disease Outcomes Quality InitiativeCardiovascular risk factorsHigher cardiovascular mortalityMajor risk factorBest available studiesCause of deathHealth care professionalsAllograft survivalGraft lossCardiovascular eventsLifestyle modificationCardiovascular mortalityImmunosuppressive agentsDrug therapyClinical acumenGeneral populationCare professionalsMajor causeDiseaseRecipientsAvailable studies
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients